Lifetime economic burden of hemophilia using a nationwide real-world healthcare data.

ABSTRACT:

Background

Patients with hemophilia require lifelong treatment, but the real-world lifetime economic burden of hemophilia remains unclear. This study aims to estimate the lifetime economic burden of hemophilia using real-world data, accounting for cost variation by disease phase and over time.

Methods

Male patients with hemophilia A (PwHa) or B (PwHb) recorded in South Korea's Health Insurance Review and Assessment (HIRA) database from 2007 to 2022 were included. Survival was estimated using the rolling extrapolation method. A phase-specific costing approach was applied, distinguishing three phases: before hemophilic arthropathy (BH), after hemophilic arthropathy (AH), and 1 year before death (BD). Transition probabilities from BH to AH were calculated based on incidence rat

SUBMITTER: Byun JY 

PROVIDER: S-EPMC12500110 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature